Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C
Authors:
- 1 May 2008
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 20 (5) , 373-378
Abstract
Objectives Serum levels of soluble interleukin-2 receptor (sIL-2R) are known to serve as a marker for the activation of T lymphocytes. We measured serum levels of sIL-2R in patients with chronic hepatitis C (CHC) during interferon (IFN)-based treatment to determine the correlation between those levels and therapeutic efficacy, and to clarify whether there is a difference in the activation of T lymphocytes among HCV genotypes after the treatment. Methods Forty-four patients received IFN-α2b monotherapy (group IFN-M), whereas 82 patients received the combination therapy with IFN-α2b and ribavirin (group IFN+R). We measured serum sIL-2R levels in these patients before (T0) and 2 weeks (T2) after the treatment. Results The sustained virologic response rates in genotype 2a/2b patients were significantly higher than those in genotype 1b patients in both groups (PT2 were significantly higher than those at T0 in both groups (PT2 were not different from those at T0 in group IFN-M, but were significantly higher than those at T0 in group IFN+R (P=0.0072). In genotype 1b patients, sIL-2R levels at T2 were not different from those at T0 in group IFN-M, but were significantly higher than those at T0 in group IFN+R (P=0.0064). In genotype 2a/2b patients, sIL-2R levels at T2 were significantly higher than those at T0 in both groups (P<0.0005). Conclusion These findings suggest that the activation of T lymphocytes after IFN-based treatment contributes to a high-sustained virologic response rate, especially in genotype 2a/2b patients.Keywords
This publication has 47 references indexed in Scilit:
- Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 UpdateJournal of Viral Hepatitis, 2001
- Analysis of Successful Immune Responses in Persons Infected with Hepatitis C VirusJournal of Experimental Medicine, 2000
- Racial differences in responses to therapy with interferon in chronic hepatitis CHepatology, 1999
- Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistenceHepatology, 1999
- Quantitative analysis of hepatitis C virus-specific CD8+T cells in peripheral blood and liver using peptide-MHC tetramersProceedings of the National Academy of Sciences, 1999
- Predictors of sustained response to alpha interferon therapy in chronic hepatitis CJournal of Hepatology, 1998
- Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis CJournal of Medical Virology, 1998
- Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparisonHepatology, 1997
- The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis CJournal of Molecular Medicine, 1996
- Factors Affecting Treatment Responses to Interferon- in Chronic Hepatitis CThe Journal of Infectious Diseases, 1996